[go: up one dir, main page]

AU2001237543A1 - Proteins, genes and their use for diagnosis and treatment of schizophrenia - Google Patents

Proteins, genes and their use for diagnosis and treatment of schizophrenia

Info

Publication number
AU2001237543A1
AU2001237543A1 AU2001237543A AU3754301A AU2001237543A1 AU 2001237543 A1 AU2001237543 A1 AU 2001237543A1 AU 2001237543 A AU2001237543 A AU 2001237543A AU 3754301 A AU3754301 A AU 3754301A AU 2001237543 A1 AU2001237543 A1 AU 2001237543A1
Authority
AU
Australia
Prior art keywords
schizophrenia
genes
diagnosis
proteins
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001237543A
Inventor
Herath Mudiyanselage Athula Chandrasiri Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Jonathan Alexander Terrett
Kerry Louise Tyson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001237543A1 publication Critical patent/AU2001237543A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001237543A 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia Abandoned AU2001237543A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
GB0004415 2000-02-24
US75039500A 2000-12-28 2000-12-28
US09750395 2000-12-28
PCT/GB2001/000792 WO2001062785A2 (en) 2000-02-24 2001-02-23 Protein and gene and their use for diagnosis and treatment of schizophrenia

Publications (1)

Publication Number Publication Date
AU2001237543A1 true AU2001237543A1 (en) 2001-09-03

Family

ID=26243725

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001237543A Abandoned AU2001237543A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001233954A Abandoned AU2001233954A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001233954A Abandoned AU2001233954A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia

Country Status (3)

Country Link
EP (2) EP1259607A2 (en)
AU (2) AU2001237543A1 (en)
WO (2) WO2001062785A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003028543A2 (en) * 2001-10-03 2003-04-10 Pfizer Products Inc. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
AU2003223184A1 (en) 2002-02-21 2003-09-09 Fujisawa Pharmaceutical Co., Ltd. Methods of preventing or treating brain ischemia or brain injury
CN1300588C (en) * 2005-02-28 2007-02-14 上海交通大学 Method for acquiring plasma specific protein for schizophrenia diagnosis and use thereof
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
DK2370088T3 (en) 2008-12-27 2017-02-20 Pawan Saharan Nanopeptides derived from mammalian colostrum for broad-spectrum viral and recurrent infections and methods for isolation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp
AU4480997A (en) * 1996-09-13 1998-04-02 Mount Sinai School Of Medicine Of The City University Of New York, The Screening methods for compounds useful in the treatment of schizophrenia
WO1998040748A1 (en) * 1997-03-14 1998-09-17 Neuromark Diagnosing neurologic disorders
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
EP1012300A1 (en) * 1997-09-05 2000-06-28 Acorda Therapeutics Hnk-1 sulfotransferase and methods of use therefor
IL134968A0 (en) * 1997-09-17 2001-05-20 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU7508100A (en) * 1999-10-04 2001-05-10 Jens Andersen Human seizure related proteins
EP1101820A1 (en) * 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds

Also Published As

Publication number Publication date
WO2001063293A3 (en) 2002-04-11
AU2001233954A1 (en) 2001-09-03
WO2001062785A3 (en) 2002-01-31
WO2001063293A2 (en) 2001-08-30
WO2001062785A2 (en) 2001-08-30
EP1259607A2 (en) 2002-11-27
WO2001063293A8 (en) 2001-10-18
EP1259818A2 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2001288249A1 (en) Biosensors and methods for their use
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001233954A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU2002251367A1 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
AU2002303262A1 (en) Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2002222308A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular response
AU2002222169A1 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma
AU2002222307A1 (en) Proteins, genes and their use for diagnosis and treatment of cardiac response
AU2001288416A1 (en) Methods and systems for facilitating the diagnosis and treatment of schizophrenia
GB0004415D0 (en) Proteins and their use for diagnosis and treatment of schizophrenia
AU2002225852A1 (en) "67118", "67067" and "62092", human proteins and methods of use thereof
AU2002245158A1 (en) Human proteins 55562 and 21617, and methods of use thereof
AU2002217110A1 (en) Fractions of snake blood, their preparation and use as therapeutic agents
AU7304000A (en) Virulence gene and protein, and their use
GB0119791D0 (en) Proteins,genes and their use for diagnosis and treatment of breat cancer